4 results about "Diosgenin" patented technology

This invention discloses a biphasic combined Lewis acid hydrolysis method for extracting diosgenin from fenugreek, belonging to the field of natural product extraction technology. The extraction method disclosed in this invention includes: defatting fenugreek raw material, mixing it with a biphasic reaction system composed of Lewis acid, concentrated hydrochloric acid, methanol, water, and petroleum ether, and carrying out a hydrolysis reaction under heating conditions. After the reaction, the organic phase is separated, concentrated, and dried to obtain diosgenin. This invention innovatively introduces a Lewis acid catalyst into the biphasic acid hydrolysis system of fenugreek, achieving significant results such as a 25% reduction in reaction time, a 50% reduction in concentrated hydrochloric acid usage, and a 25% reduction in water usage while ensuring the extraction rate of diosgenin. This method has advantages such as mild conditions, low acid consumption, short processing time, and environmental friendliness, and is suitable for the large-scale green production of diosgenin.

The application of diosgenin in the preparation of drugs for the prevention or treatment of acute kidney injury falls within the pharmaceutical field. Specifically, this invention discloses that diosgenin, by directly binding to the PIK3CA protein, regulates the PI3K / Akt-NF-κB pathway, inhibiting inflammatory responses, apoptosis, and pyroptosis in renal tubular epithelial cells, thereby alleviating kidney damage. Cellular experiments show that diosgenin at concentrations of 0.1–5 μM can significantly protect renal tubular epithelial cells; animal experiments show that doses of 1–20 mg / kg can significantly improve renal function and reduce pathological damage in mice with acute kidney injury. This invention clarifies a complete chain of evidence from "compound—target—pathway—efficacy," providing a new drug candidate for the treatment of acute kidney injury and offering a paradigm for the mechanistic study of active ingredients in traditional Chinese medicine, contributing to the transformation of traditional Chinese medicine from empirical medicine to evidence-based and molecular medicine.

This invention belongs to the field of biomedical technology, specifically relating to an umbilical cord MSC exosome nanocarrier delivery system and its application in the preparation of drugs for treating allergic rhinitis. This invention prepares the umbilical cord MSC exosome nanocarrier delivery system by adding a specific concentration of diosgenin to the culture medium of umbilical cord mesenchymal stromal cells (MSCs), collecting the cell culture supernatant, and separating and extracting it. Animal experiments show that the delivery system prepared in this invention significantly improves the symptoms of nose scratching and sneezing in mice with allergic rhinitis. Its mechanism of action lies in effectively regulating the Th1 / Th2 immune balance: significantly inhibiting the overexpression of the pro-inflammatory factor IL-4, while simultaneously restoring the anti-inflammatory factor IL-10, thus avoiding immune dysregulation. This invention provides a safe and effective new treatment for allergic rhinitis and has good clinical application prospects.